Abstract It is well-known that many members of the family of nuclear receptors have been implicated in human diseases, and metabolic disorders in particular. The NR4A nuclear receptor family consists of three members, Nur77, Nurr1, and NOR1. All of these are orphan receptors, and Nur77 and NOR1 exert possible pathological roles in immune diseases through the modulation of leukocyte functions. CD30 stimulation, which induces eosinophil-specific apoptosis, markedly enhances expression of Nur77 and NOR1 in eosinophils. This suggests the possibility of pharmacological modulation of Nur77-or NOR1-specific apoptotic pathways via receptor-dependent transactivation. In this review, we discuss treatment of allergic diseases by low molecular weight compounds acting through the NR4A receptor family to cause eosinophil apoptosis. NR4A nuclear receptor genes were selected following comprehensive analysis of differentially expressed genes in eosinophils of atopic dermatitis patients compared with healthy volunteers.
It has been reported that there are at most 400 molecular gene targets susceptible to pharmacological manipulation (Fauman et al. 2003) , the majority of which have been identified as a result of classical drug development approaches. Almost all of those identified are enzymes and receptors. Following elucidation of the entire human genome, the percentage of enzyme and receptor genes qualifying as pharmacological target genes will be finite. These receptor genes consist of plasma membrane receptors (most of which are G-protein-coupled receptors; GPCRs) and nuclear receptors; the number of nuclear receptors in the entire human genome is reported to be 48 (Maglich et al. 2001) . With regard to previous research directed at the identification of receptor ligands, the success rates in recognizing nuclear receptors as pharmacological target genes are considerably higher than in the case of GPCRs, of which several thousand exist in the human genome. Recent drug development strategies have been redirected towards the identification of gene targets before the identification of chemical structures, since all human genomic information is already available. In this context, nuclear receptors, about half of which are still orphan and whose endogenous ligands are as yet unknown, remain extremely attractive molecular targets for new medicines designed to treat a variety of diseases as well as metabolic disorders Chawla et al. 2001) .
Comprehensive gene expression analysis in eosinophils from patients with allergic diseases
Both multigene interactions and environmental factors are likely to contribute to allergic diseases. Among infiltrating cells in pathologically diseased tissue, eosinophils in particular play causative roles in conditions such as asthma (Holt et al. 1999; Gleich 2000) , atopic dermatitis (AD) (Kapp 1993; Leiferman 1994) , and rhinitis (Gefand 2004; Eliashar and Levi-Schaffer 2005) . Eosinophils are involved in tissue damage during the chronic phase of allergic diseases mediated by reactive oxygen species, lipid mediators, cytokines, and cytotoxic granular proteins such as major basic protein and eosinophil cationic protein (Bochner 2000) . However, expression analysis and functional studies of disease-related genes in these cells have not been carried out systematically to date. This is because the study of gene expression in eosinophils presents some difficulties in that the percentage of these cells in healthy peripheral blood is very low (less than 3%). In addition, no appropriate cell lines are available for further in vitro functional studies, other than leukemic cell lines such as Eol1 (Saito et al. 1985) and AML14.3D10 (Baumann and Paul 1998) . Recent developments in the technology of gene expression analysis, such as differential display (DD) (Liang and Pardee 1992; Ito et al. 1994) , DNA microarray (Schmidt-Weber et al. 2001; Granucci et al. 2001) , and real-time RT-PCR (Lie and Petropoulos 1998; Kafert et al. 1999 ) make it possible to efficiently survey the expression of large numbers of genes in small amounts of clinical samples, and new data on eosinophil accumulation and actions in pathological conditions are being accumulated.
Using the techniques described above, we at Genox Research Inc. have established systems for directly analyzing the expression of various genes in clinical samples, such as fractionated peripheral blood ) and skin biopsies Ogawa et al. 2005) obtained from allergic patients. These studies have revealed some novel genes implicated in performing essential roles in the pathological conditions characteristic of allergic diseases (Matsumoto et al. , 2004a Heishi et al. 2002; Imai et al. 2002; Hashida et al. 2003; Nagata et al. 2003; Ogawa et al. 2004; Kagaya et al. 2005a) . A successful example of this approach has been the identification of the nuclear receptor gene family whose enhanced expression in peripheral blood eosinophils correlated with the pathological condition of AD. We will discuss not only the pathological importance of these genes, but also the possibility that these nuclear receptors may constitute novel pharmacological targets in strategies used to develop anti-allergic drugs.
The distinguishing feature of comprehensive gene expression analysis using DD or GeneChip methods lies in the likelihood of finding unexpected novel genes. However, the disadvantage of such an approach is that it cannot be determined whether a given change in gene expression is a cause or an effect of the disease in question. In the case of diagnostic marker genes, this does not matter. However, functional analyses are necessary to clarify whether or not a particular gene is a genuinely important potential pharmacological target of the disease. For these purposes, new techniques such as gene knockout (KO) or gene overexpression at both the cellular level and in animal models are useful approaches for clarifying gene function and validating the importance of genes in disease etiology. The strategy used when validating NR4A nuclear receptor family genes as targets for pharmacological manipulation in the treatment of allergic diseases is outlined below.
Nuclear receptors in eosinophils
DD and subsequent GeneChip analysis comparing gene expression in diseased samples with expression in healthy samples has been effective in the identification of new druggable genes in allergic diseases. We picked up 24 genes among a total of more than 10,000 genes in GeneChip by comparing highly purified peripheral blood eosinophils of AD patient samples with those from healthy volunteers (Kagaya et al. 2005a) . While there were no GPCRs among the 24, two nuclear receptors in the same NR4A orphan nuclear receptor family, Nur77 and NOR1, were identified. Using a larger number of samples, the expression of both receptor genes was measured by real-time RT-PCR. Nurr1, another member of the NR4A family, was not identified by GeneChip analysis. However, real-time RT-PCR demonstrated higher expression levels of Nurr1 in eosinophils from AD patients than in those from healthy volunteers. NOR1 had a particularly interesting expression profile, because it was the only receptor found to be eosinophil-specific among peripheral blood leukocyte fractions. Differences in NOR1 gene expression were also found by comparative DD analysis of eosinophils in the same patients during the exacerbation and remission phases of AD. NOR1 expression was remarkably elevated by bedside treatment, an effect accompanied by a dramatic decrease in the number of eosinophils in peripheral blood of these patients.
It appears to be unprecedented that the presence of a nuclear receptor family correlates specifically with the pathology of an allergic disease. There are few reports of nuclear receptors in eosinophils, apart from a report by Ueki et al. (2003) of the presence of peroxisome proliferator-activated receptor gamma (PPARc). Recent evidence has suggested that PPARc serves as a negative regulator in the immune system, while positively regulating adipogenesis and lipid metabolism in adipocytes (Forman et al. 1995; Kliewer et al. 1995) . These authors provided interesting evidence that purified eosinophils express the nuclear receptor at mRNA and protein levels. Furthermore, the PPARc agonist troglitazone inhibited IL-5-stimulated (but not basal) eosinophil survival and eotaxin-directed chemotaxis. Inducing apoptosis of inflammatory cells through such specific nuclear receptors is an attractive approach and one which may constitute a goal in future treatment of allergic diseases. However, PPARc expression and PPARc-mediated apoptosis are not eosinophil-specific; furthermore, PPARc agonists are suggested to also act through distinct pathways other than PPARc (Takeda et al. 2001) . Therefore, the functions of this nuclear receptor need to be clarified further.
It is very suggestive that two among three family members were selected from more than 10,000 genes. All three NR4A nuclear receptor members are immediate-early genes which are poorly expressed under basic conditions in many tissues and cells, and induced within a few hours by various stimuli. NOR1 in particular is present at low copy number in nascent eosinophils, and expression levels increase rapidly on stimulation. Nevertheless, it could not be concluded from the clinical sample data alone whether expression of the NOR1 gene occurred as a cause or an effect; these receptors are thought to be related to regulation of eosinophil numbers in peripheral blood via apoptotic regulation of the cells.
Apoptotic characteristics of the NR4A nuclear receptor
Among the three genes (Nur77, Nurr1, and NOR1) which constitute the NR4A nuclear receptor family, Nur77 and Nurr1 have similar molecular biological characteristics, in that both receptors function as transcription factors forming heterodimers with retinoic X receptor (RXR) (Perlmann and Jansson 1995; Zetterstrom et al. 1996a; Vivat et al. 1997; Maira et al. 1999) . They can mediate efficient transactivation through a DR-5 element in response to the RXRspecific ligand, 9-cis retinoic acid. On the other hand, the third member, NOR1, does not appear to interact with RXR, but functions as a homodimer or a monomer. Recently, Nurr1 has emerged as a possible target gene in Parkinson's disease (Kim et al. 2002) , a condition known to be related to differentiation of dopaminergic neurons (Zetterstrom et al. 1996b; Saucedo-Cardenas et al. 1998) ; however, roles for Nurr1 in blood cells are almost unknown. On the contrary, there is evidence that Nur77 and NOR1 appear to function similarly in cells, because both molecules reportedly have apoptotic characteristics in immune cells (Cheng et al. 1997; Steff et al. 2001; He 2002; Winoto and Littman 2002) . It follows that they may be implicated in disorders related to genetically or environmentally induced defects of activation-induced cell death (AICD), such as autoimmune diseases. Nur77 functions were firstly elucidated in T cells, where the gene is involved in CD3-induced cell apoptosis, or AICD signaling. Similarly, NOR1 was also found to be induced in T cells via the same signaling pathway.
The roles of this receptor family in eosinophil functions have not yet been clarified. CD30 stimulation has recently been shown to cause eosinophil-specific apoptosis (Matsumoto et al. 2004b ). It has been further reported that CD30 stimulation markedly induced Nur77 and NOR1 during eosinophil-specific apoptosis (Kagaya et al. 2005a ). However, CD30 stimulation did not alter Nurr1 expression in this system. Fas signaling has also been shown to induce eosinophil apoptosis, but this effect is not eosinophil-specific; nor were Nur77 or NOR1 induced before apoptosis under these circumstances. Gene expression of the NR4A nuclear receptor family and subsequent eosinophil apoptosis were downregulated by a MAPK inhibitor, but not by a p38 inhibitor. ERK1/2 phosphorylation by MEK1/2 downstream of CD30 signaling and upstream of the nuclear receptor family may be involved in apoptosis, but we still have no information on events downstream of these nuclear receptors.
Human NOR1 transgenic (TG) mice, into which ten copies of the actin promoter-constructed NOR1 gene had been incorporated, showed drastic phenotype changes. The TG mice were small with a body weight approximately half that of wild-type mice, and their thymuses and spleens showed evidence of dramatic atrophy (Kagaya et al. 2005b ). Furthermore, NOR1 may be a semi-lethal gene, because the live birth ratio of the transgenic mice was less than 50%. In addition, spleen cells of the TG mice were susceptible to apoptotic stimuli in culture. Though the precise regulatory mechanism is unknown, over-expression of NR4A nuclear receptors appears to regulate the downstream event following NR4A expression and induce cell death. Besides regulation of expression, it is speculated that their functions could be regulated through unknown endogenous agonists or synthetic low molecular weight compounds which directly bind their ligandbinding domains (LBDs).
Transactivation of NR4A nuclear receptors and induction of apoptosis NR4A orphan nuclear receptors may not be genuinely orphan in nature, and an endogenous ligand may exist close to where these receptors are highly expressed. Such a hypothesis has been confirmed for chenodeoxycholic acid, which has been identified as an FXR ligand in liver, a region where the NR1H family member FXR is highly expressed (Makishima et al. 1999; Parks et al. 1999) . Thus lipid mediators such as arachidonate and glycerolipid cascade metabolites, possibly induced in activated leukocytes following pathological stimuli, were screened. For screening, a mammalian hybrid system in which GAL4-NR4A receptor-linked chimera plasmids and the GAL4 binding domain-firefly luciferase reporter plasmid were cotransfected into cultured cells was used, and luciferase activity after ligand candidate addition was assayed. Only prostaglandin (PG) A 2 was found to have NR4A nuclear receptor-dependent transactivation activity in this system (Kagaya et al. 2005b) .
PGA 2 (3-10 lM) acted as a potent activator of NOR1 transcription through the GAL4-based reporter system, and LBD-deleted receptor showed little transcriptional activation by PGA 2 . The putative LBD of receptor was also proved to directly bind PGA 2 using high-resolution Biacore S51. Evaluation of the effects of PGA 2 -like cyclopentenone derivatives on NR4A-dependent transcription demonstrated that there are subtype-specific transactivators and clear structureactivity relationships, as assessed by minor modification of the functional groups in these very similar PG structures. A recent report using X-ray crystallographic analysis of the Nurr1 LBD demonstrated that it lacked a binding site for low molecular weight ligands (Wang et al. 2003) . Although no information is currently available on the NOR1 LBD structure, NOR1 may lack a typical binding site conserved among steroid receptors, because the amino acid sequences are similar to the Nurr1 LBD. The evidence that the N-terminal AF-1 domain-deleted construct of NOR1 lost transcriptional activation by PGA 2 suggests that the effects of PGA 2 may require both the LBD and AF-1 domains of NOR1. Wansa et al. (2002 Wansa et al. ( , 2003 also demonstrated that the NR4A N-terminal AF-1 domain supports efficient recruitment of the co-activator complex necessary for transcriptional activity. Furthermore, the AF-1 domain was shown to interact directly with the C-terminal LBD domain (Maira et al. 2003) . The above reports suggest an alternative explanation: that PGA 2 transactivates NOR1 through AF-1-dependent co-activator recruitment and crosstalk between the AF-1 and LBD domains.
There is still no direct evidence as to whether exogenous PGA 2 or its derivatives induce apoptosis in NOR1-expressing eosinophils. However, when PGA 2 -induced cell death in NOR1 TG mice was examined, it was surprisingly found that PGA 2 showed strong effects on cell viability in spleen cells derived from these mice. This effect of PGA 2 observed in the NOR1 TG mice was significantly greater than that in wild-type mice. These findings suggest a specific molecular linkage between PGA 2 and NOR1, and in turn suggest possible therapeutic targets for the discovery of important new pharmacological agents. A scheme for the discovery of such anti-allergic agents is shown in Fig. 1 .
Cyclopentenone PG derivatives including PGA 2 have diverse pharmacological activities and manifest expected quantitative structure-activity relationships with respect to stimulation of neurite outgrowth (Satoh et al. 1999) , antiviral function (Santoro 1997) , and anticancer activity (Fukushima 1992) . However, research in these areas is no longer topical because of the lack of success in identifying molecular targets to date. It has also been reported that PGA 2 has apoptotic activity in some cells, though the definitive signaling cascade has not yet been elucidated. Previous reports have shown that PGA 2 induces p21 Cip1 expression, suppresses cyclin D1 expression, and induces G1 arrest in proliferating cells (Hitomi et al. 1998; Tanikawa et al. 1998; Lin et al. 2000) . Observations that the effects of PGA 2 (induction of p21 Cip1 , suppression of cyclin D1, and induction of cell death) were enhanced in spleen cells derived from NOR1 TG mice suggest that the effects of PGA 2 are influenced, at least in part, by the expression levels of NOR1.
Strategies used to develop anti-allergic drugs active at NR4A nuclear receptors
The discovery of the existence of low molecular transactivators for these nuclear receptors and quantitative structure-activity relationships suggest that it will be possible to develop anti-allergic drugs by designing and screening agonists for these receptors.
NOR1 is the most promising target among NR4A receptors because it is eosinophil-specific. The strategy of specifically attacking and removing eosinophils was first attempted using an anti-IL-5 monoclonal antibody. Treatment with the antibody drastically reduced the numbers of circulating and sputum eosinophils, but did not improve airway responses in asthma patients (Leckie et al. 2000) . These studies provoked a scientific controversy regarding the importance of eosinophils in the development of asthma. On the other hand, a recent study has proved that a significant number of eosinophils exist in the bronchial mucosa in asthmatic patients treated with anti-IL-5 antibody (Flood-Page et al. 2002) . In support of these findings, Liu et al. (2002) have also reported the loss of IL-5 receptor a on airway eosinophils after allergen challenge, which may explain the ineffectiveness of anti-IL-5 antibody. If eosinophil deletion could be achieved by treatment with low molecular weight chemicals, which might penetrate more easily into peripheral inflammatory tissues, the significance of the role of eosinophils would be established, and the controversy would be resolved. Recent reports in mutant eosinophil-deleted mice established that these mice did not exhibit signs of airway remodeling, even after continuous antigen challenge (Lee et al. 2004; Humbles et al. 2004) . Airway remodeling in asthma involves well-defined chronic structural airway changes, including glandular increases within the airways, enhanced collagen deposition within the lamina propria, and an increase in the airway vasculature in conjunction with airway smooth muscle hypertrophy and hyperplasia (Holgate 2002; Homer and Elias 2005; Pascual and Peters 2005) . While the above pathology is characteristic of asthma, diagnostic approaches to airway remodeling are now developing, for example using high-resolution CT scanning (Jaffuel et al. 2001) . The strategy of provoking eosinophil-specific apoptosis may be effective when targeting airway remodeling in asthma, and may therefore become a novel treatment for chronic asthma.
These approaches might be applied not only to asthma but also to nasal polyps accompanied by allergic asthma and to atopic dermatitis, in which the roles of eosinophils are less clear than in the pathology of asthma. In fact, we have preliminary data that surgically removed nasal polyps containing large eosinophil accumulations expressed more than 100-fold higher amounts of NOR1 compared with other sections. On the other hand, Genox Research Inc. have also generated an expression profile database of lesional skin biopsy samples compared with non-lesional skin from more than ten AD patients Ogawa et al. 2005) . NOR1 was dominantly expressed in these lesional skin samples. Though the role of eosinophil infiltration in AD skin lesions is not sufficiently elucidated, it is worthy of further study.
The most recent successful milestones in molecular biological nuclear receptor pharmacology relate to our understanding of PPARc function and the discovery of thiazolidine derivatives as antidiabetic agents for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). There are some counter arguments about the role of 15-deoxy delta 12,14 PGJ 2 as an endogenous ligand of PPARc (Bell-Parikh et al. 2003) . However, the finding that PGA 2 , another cyclopentenone-type PG pathway metabolite (whose receptor is not clearly defined), caused transactivation of the NOR1 receptor is most persuasive. The molecular target of anti-NID-DM thiazolidine derivatives was identified only after development of this drug class. Thus, it represents a significant challenge to identify a non-PG type NOR1 transactivator using pharmacophore information, virtual screening technology, and high-throughput screening, and to develop such compounds as antiallergic drugs via the drug development schemes outlined in Fig. 2 .
At the present time, we can only offer the hypothesis that PGA 2 localizes in high concentrations in leukocytes such as the eosinophil and acts as a true endogenous ligand of the NR4A nuclear receptor in these cells. This is because we have no information regarding actual concentrations of this substance in activated leukocytes. A fixed proportion of adult asthma cases are induced by nonsteroidal anti-inflammatory drugs (NSAIDs), and it is not known why NSAIDs have this action. We now know that the lipoxygenase pathway becomes dominant and leukotriene Fig. 1 Working hypotheses for eosinophil-specific apoptosis through the NOR1 nuclear receptor. Our findings suggest a specific molecular linkage between PGA 2 and NOR1, and also suggest possible therapeutic targets for the discovery of important new pharmacological agents through the modulation of eosinophil apoptosis production is increased in inflammatory cells by NSAIDs which suppress the PG pathway during arachidonate metabolism (via cyclooxygenase inhibition), and this exacerbates asthmatic symptoms. However, is this theory really enough to explain the clinical phenomena? It is said that nasal polyps, which constitute an accumulation of eosinophils, are induced in a high percentage of aspirin-induced asthma cases. It may be that NSAIDs locally block production of the endogenous cyclopentenone-type PG in inflammatory cells; this leads to dysregulated eosinophil turnover in inflammatory sites through apoptosis, and significant accumulation of eosinophils takes the form of nasal polyps in inflammatory lesions. While the hypotheses outlined above are attractive, their application to the design of successful novel anti-allergic therapeutic strategies will provide proof of their veracity.
Concluding remarks
Nuclear receptors are among the most promising pharmacological target genes. Specific compounds that regulate NOR1-dependent transcriptional activity have the potential to be used as treatments for cancers and immunological disorders. By combining our information from gene suppression techniques, NOR1 may also be a promising target in the treatment of allergic diseases. Although the members of the NR4A family have been regarded as constitutive activators until now, new findings and hypotheses suggest that NR4A nuclear receptor pathways are subject to pharmacological modulation by low molecular weight compounds. Promising novel compounds active at NOR1 nuclear receptors will inform future therapeutic strategies for NR4A-related human disorders. Fig. 2 Strategies for drug discovery through nuclear receptor research. This scheme shows the significant challenge involved in identifying a non-PG type NOR1 transactivator using pharmacophore information, virtual screening technology, and high-throughput screening, and in developing low molecular compounds as anti-allergic drugs, reproducing the success of thiazolidinediones as anti-NIDDM drugs
